Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

79 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Establishment of a formal program for retinoblastoma: Feasibility of clinical coordination across borders and impact on outcome.
Al-Haddad C, Bashour Z, Farah L, Bayram L, Merabe Z, Ma'luf R, Alameddine R, Eid T, Geara F, Wilson M, Brennan R, Jeha S, Ghanem K, Yousef RA, Farah R, Noun P, Yassine N, Inati A, Muwakkit S, Abboud M, Tarek N, Hamideh D, Saab R. Al-Haddad C, et al. Among authors: inati a. Pediatr Blood Cancer. 2019 Nov;66(11):e27959. doi: 10.1002/pbc.27959. Epub 2019 Aug 18. Pediatr Blood Cancer. 2019. PMID: 31423715
Dorfman-Chanarin syndrome: case report with multisystem involvement.
Hassoun M, El ZZ, Noun P, Beani M, Fakhoury H, Mouawad P, Inati A. Hassoun M, et al. Among authors: inati a. Pediatr Ann. 2008 May;37(5):353-7, 359-60. doi: 10.3928/00904481-20080501-11. Pediatr Ann. 2008. PMID: 18543546 No abstract available.
13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study.
De Montalembert M, Abboud MR, Fiquet A, Inati A, Lebensburger JD, Kaddah N, Mokhtar G, Piga A, Halasa N, Inusa B, Rees DC, Heath PT, Telfer P, Driscoll C, Al Hajjar S, Tozzi A, Jiang Q, Emini EA, Gruber WC, Gurtman A, Scott DA. De Montalembert M, et al. Among authors: inati a. Pediatr Blood Cancer. 2015 Aug;62(8):1427-36. doi: 10.1002/pbc.25502. Epub 2015 Mar 23. Pediatr Blood Cancer. 2015. PMID: 25810327 Clinical Trial.
Safety and efficacy of voxelotor in pediatric patients with sickle cell disease aged 4 to 11 years.
Estepp JH, Kalpatthi R, Woods G, Trompeter S, Liem RI, Sims K, Inati A, Inusa BPD, Campbell A, Piccone C, Abboud MR, Smith-Whitley K, Dixon S, Tonda M, Washington C, Griffin NM, Brown C. Estepp JH, et al. Among authors: inati a. Pediatr Blood Cancer. 2022 Aug;69(8):e29716. doi: 10.1002/pbc.29716. Epub 2022 Apr 21. Pediatr Blood Cancer. 2022. PMID: 35451176
Ticagrelor vs placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: the HESTIA3 study.
Heeney MM, Abboud MR, Githanga J, Inusa BPD, Kanter J, Michelson AD, Nduba V, Musiime V, Apte M, Inati A, Taksande AM, Andersson M, Åstrand M, Maklad N, Niazi M, Himmelmann A, Berggren AR. Heeney MM, et al. Among authors: inati a. Blood. 2022 Sep 29;140(13):1470-1481. doi: 10.1182/blood.2021014095. Blood. 2022. PMID: 35849650 Free PMC article. Clinical Trial.
79 results